Key result
CYP3A5*3 homozygosity is linked to greater CK elevation in atorvastatin-induced myalgia.
Case-Control (n=137)
No
Answers are grounded in this paper and cite their sources.
Retrospective case-control study reveals CYP3A5*3 homozygosity increases atorvastatin-induced muscle damage severity in patients with myalgia, indicating pharmacogenetic risk for statin toxicity.
Atorvastatin is metabolized through enzymes encoded by members of the cytochrome P-450 (CYP) 3A gene family. Some patients who take atorvastatin along with concomitant medications known to inhibit CYP3A enzyme activity (e.g. itraconazole) develop rhabdomyolysis secondary to a severe drug-induced myopathy. The present study aimed to characterize the relationship between CYP3A gene polymorphisms and atorvastatin-induced muscle damage in the context of concomitant medication. The study employed a retrospective case--control (n=137) design. Study subjects were recruited from the general patient population served by Marshfield Clinic, a large horizontally integrated multispecialty group practice located in central Wisconsin, and case assignment was based upon both subjective (myalgia) and objective inclusion criteria [elevated serum creatine kinase (CK) levels]. The primary outcome was the relationship between serum CK level and CYP3A genotype. CYP3A genotype was not associated with an increased risk for the development of atorvastatin-induced muscle damage. CYP3A4*1B and CYP3A5*3 allele frequencies were similar in cases (n=68) and controls (n=69). Conversely, CYP3A genotype was associated with an increased severity of atorvastatin-induced muscle damage. An association was identified between the non-functional CYP3A5*3 allele and the magnitude of serum CK elevation in case patients experiencing myalgia. Patients who were homozygous for CYP3A5*3 demonstrated greater serum CK levels than patients who were heterozygous for CYP3A5*3, when concomitant lipid-lowering agents were sequentially removed from the analysis (P=0.025 without gemfibrozil, P=0.010 without gemfibrozil and niacin). The study demonstrates that patients who develop myalgia while taking atorvastatin are more likely to experience a greater degree of muscle damage if they express two copies of CYP3A5*3.
No takes yet. Share an insight, caveat, or question.
Wilke et al. (2005) conducted a case-control in Atorvastatin-induced muscle damage (n=137). CYP3A5*3 homozygosity vs. CYP3A5*3 heterozygosity was evaluated on Relationship between serum creatine kinase (CK) level and CYP3A genotype (p=0.010). CYP3A5*3 homozygosity was associated with greater serum CK elevation than heterozygosity in patients with atorvastatin-induced myalgia.
Synapse has enriched 10 related papers. Consider them for comparative context: